Abstract
Modulation of apoptosis through altered expression of Bcl-2 and/or Bax may be a mechanism by which dehydroepiandrosterone (DHEA) administration and calorie restriction (CR) exert their chemopreventive effects in p53-deficient (p53-/-) mice. Using immunohistochemical detection we found that treatment with both DHEA and CR resulted in decreased expression of the PCNA proliferation marker in the thymus. In addition, treatment with DHEA also increased the rate of apoptosis in the thymus, resulting in marked thymic atrophy. Thus, both DHEA and CR appear to shift cell number homeostasis by favoring apoptosis. To further understand the molecular mechanisms by which DHEA and CR exert their effects, we examined two components of the apoptotic pathway, Bcl-2 and Bax. We found that p53-/- mice have much higher levels of Bcl-2 mRNA in the thymus than wild-type (p53+/+) mice. Treatment of p53-/- animals with DHEA resulted in decreased Bcl-2 but not Bax mRNA levels in the thymus. In contrast, CR did not change either Bcl-2 or Bax mRNA expression. The present study provides molecular evidence that DHEA and CR may modulate tumorigenesis through alterations in the apoptotic and/or proliferative pathways.
References
Mar 29, 1992·Nature·L A DonehowerA Bradley
Jul 5, 1991·Science·M HollsteinC C Harris
Jun 6, 1991·Nature·A J LevineC A Finlay
Oct 10, 1986·Cell·M L ClearyJ Sklar
Feb 1, 1995·Current Opinion in Genetics & Development·R Haffner, M Oren
Jan 1, 1994·Journal of Cell Science. Supplement·M L Hooper
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·T SatoH G Wang
Oct 21, 1994·Cell·A StrasserS Cory
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·S D HurstingJ M Phang
May 15, 1993·Lancet·D A Carson, J M Ribeiro
Jan 1, 1994·The Journal of Cell Biology·J C Reed
Aug 27, 1993·Cell·Z N OltvaiS J Korsmeyer
Oct 22, 1993·Cell·D J VeisS J Korsmeyer
Citations
Nov 5, 1999·Archives of Pharmacal Research·S H KimH M Rheu
Jul 2, 1999·Comparative Biochemistry and Physiology. Part C, Pharmacology, Toxicology & Endocrinology·Y R Lea-CurrieM K Mcintosh
Feb 28, 2001·The Journal of Steroid Biochemistry and Molecular Biology·N C YangM L Hu
Jul 23, 1999·Mutation Research·S D Hursting, F W Kari
Feb 26, 1999·Journal of the National Cancer Institute·S D HurstingJ M Phang
Jun 15, 2007·Acta Tropica·Carla Domingues SantosJosé Clóvis do Prado
Mar 9, 2005·The FEBS Journal·Estrella ZapataRebeca López-Marure
Sep 8, 2004·International Immunopharmacology·Jun LiangYayi Hou
Jul 2, 2005·Mutation Research·Stephen D HurstingJ Carl Barrett
Jul 24, 2008·Dose-response : a Publication of International Hormesis Society·Okom Nkili F C Ofodile
Apr 29, 2015·Oncogene·M F RileyG Lozano
Apr 26, 2005·Life Sciences·Yun WangLai K Leung
Feb 24, 2001·Toxicologic Pathology·S D HurstingB J Davis
Nov 14, 2000·Molecular Carcinogenesis·J C ShenS D Hursting
Mar 28, 2018·Cancer Cell International·Chaoqun CenXiaorong Li
Jun 27, 2018·Endocrine-related Cancer·Jonathan W Nyce
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Madhu MazumdarGeorge J Bosl
Apr 21, 2001·Oncogene·Y WuL M Boxer
May 18, 1999·The Journal of Biological Chemistry·V Budhram-MahadeoD S Latchman
Oct 12, 2018·Endocrine-related Cancer·Jonathan W Nyce
Nov 6, 2001·The Journal of Nutrition·S D HurstingJ C Barrett
Dec 1, 2004·The Journal of Nutrition·Arti C PatelStephen D Hursting
Feb 20, 2004·Cancer Research·Henry J ThompsonWeiqin Jiang
Aug 31, 2004·The Journal of Nutrition·Stephen D HurstingSusan N Perkins